Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Assets (2018 - 2025)

Bicycle Therapeutics' Other Non-Current Assets history spans 8 years, with the latest figure at $12.8 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 15.63% year-over-year to $12.8 million; the TTM value through Dec 2025 reached $12.8 million, up 15.63%, while the annual FY2025 figure was $12.8 million, 15.63% up from the prior year.
  • Other Non-Current Assets reached $12.8 million in Q4 2025 per BCYC's latest filing, down from $13.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.8 million in Q2 2025 to a low of $2.2 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $7.8 million, with a median of $6.5 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: surged 151.69% in 2023, then tumbled 45.83% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.4 million in 2021, then soared by 145.3% to $8.5 million in 2022, then plummeted by 31.52% to $5.8 million in 2023, then soared by 91.19% to $11.1 million in 2024, then grew by 15.63% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Other Non-Current Assets are $12.8 million (Q4 2025), $13.7 million (Q3 2025), and $13.8 million (Q2 2025).